Heparin-induced thrombocytopenia in patients with Philadelphia-negative myeloproliferative disorders and unusual splanchnic or cerebral vein thrombosis

Acta Haematol. 2010;123(3):140-5. doi: 10.1159/000280466. Epub 2010 Feb 4.

Abstract

Background: Philadelphia-negative myeloproliferative disorders (Ph-MPD) are common causes of unusual splanchnic or cerebral vein thrombosis, which is treated with unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH). Heparin-induced thrombocytopenia (HIT) is a dangerous potential complication of this therapy, but it has rarely been reported in Ph-MPD.

Patients and methods: We retrospectively reviewed clinical records of 29 patients with Ph-MPD who have been treated with UFH or LMWH for unusual splanchnic or cerebral vein thrombosis (3 cerebral sinus, 6 portal and 20 hepatic vein). The goal of the study was to determine the occurrence of new thrombotic events during heparin therapy secondary to HIT (HITT).

Results: During heparin therapy, 5 out of the 29 patients (17%) developed a new thrombotic episode (pulmonary embolism) with a high clinical probability of HIT based on the 4 T's score even though not all the patients developed 'true' thrombocytopenia. A diagnosis of HIT was established in 2 patients (6.8%) through the presence of heparin-related antibodies.

Conclusions: Ph-MPD patients on heparin warrant careful monitoring and HIT has to be suspected whenever platelet counts drop or a new thrombosis is detectable.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anticoagulants / adverse effects*
  • Anticoagulants / immunology
  • Anticoagulants / therapeutic use
  • Budd-Chiari Syndrome / complications
  • Budd-Chiari Syndrome / drug therapy
  • Drug Monitoring
  • Female
  • Heparin / adverse effects*
  • Heparin / immunology
  • Heparin / therapeutic use
  • Heparin, Low-Molecular-Weight / adverse effects
  • Heparin, Low-Molecular-Weight / immunology
  • Heparin, Low-Molecular-Weight / therapeutic use
  • Humans
  • Intracranial Thrombosis / complications
  • Intracranial Thrombosis / drug therapy
  • Male
  • Middle Aged
  • Myeloproliferative Disorders / complications*
  • Platelet Count
  • Polycythemia Vera / complications
  • Pulmonary Embolism / epidemiology*
  • Pulmonary Embolism / etiology
  • Pulmonary Embolism / prevention & control
  • Retrospective Studies
  • Thrombocythemia, Essential / complications
  • Thrombocytopenia / chemically induced*
  • Thrombocytopenia / etiology
  • Thrombocytopenia / immunology
  • Thrombosis / complications
  • Thrombosis / drug therapy*
  • Time Factors
  • Young Adult

Substances

  • Anticoagulants
  • Heparin, Low-Molecular-Weight
  • Heparin